Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Mar;43(3):409-412.
doi: 10.1002/cac2.12398. Epub 2022 Dec 24.

Serologic status and safety of inactivated Covid-19 vaccine for hepatocellular carcinoma patients with cirrhosis after curative liver resection

Fuchen Liu  1 , Xiaochen Feng  1 , Jin Du  1 , Minghao Ruan  1 , Hui Liu  1
Affiliations

Serologic status and safety of inactivated Covid-19 vaccine for hepatocellular carcinoma patients with cirrhosis after curative liver resection

Fuchen Liu et al. Cancer Commun (Lond). 2023 Mar.
No abstract available

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

Figures

FIGURE 1
FIGURE 1
Serologic status and safety of inactivated Covid‐19 vaccine in patients with cirrhosis after curative liver resection for HCC. (A) The seropositive rates in controls and cirrhotic patients with HCC, respectively (left panel), and four independent factors for seronegative response to inactivated Covid‐19 vaccine in cirrhotic patients with HCC (right panel). (B) Liver function assessment in patients with cirrhosis before and after Covid‐19 vaccination. (C) Tumor serum markers assessment in patients with cirrhosis before and after Covid‐19 vaccination. (D) Local and systemic adverse effects (mild‐to‐moderate) in all the participants post‐two doses of inactivated Covid‐19 vaccine. * represents P <0.05 and *** represents P <0.001. Abbreviations: Covid‐19, coronavirus disease 2019; HCC, hepatocellular carcinoma; TBIL, total bilirubin; ALT, alanine aminotransferase; AST, aspartate aminotransferase; AFP, alpha‐fetoprotein; PIVKA‐II, protein driven through vitamin K absence or antagonist‐II; ns, not significant.
See this image and copyright information in PMC

References

    1. Cornberg M, Buti M, Eberhardt CS, Grossi PA, Shouval D. EASL position paper on the use of COVID‐19 vaccines in patients with chronic liver diseases, hepatobiliary cancer and liver transplant recipients. J Hepatol. 2021;74(4):944‐51. - PMC - PubMed
    1. Fix OK, Blumberg EA, Chang KM, Chu J, Chung RT, Goacher EK, et al. American Association for the Study of Liver Diseases Expert Panel Consensus Statement: Vaccines to Prevent Coronavirus Disease 2019 Infection in Patients With Liver Disease. Hepatology. 2021;74(2):1049‐64. - PMC - PubMed
    1. Marjot T, Webb GJ, ASt Barritt, Moon AM, Stamataki Z, Wong VW, et al. COVID‐19 and liver disease: mechanistic and clinical perspectives. Nat Rev Gastroenterol Hepatol. 2021;18(5):348‐64. - PMC - PubMed
    1. Ai J, Wang J, Liu D, Xiang H, Guo Y, Lv J, et al. Safety and Immunogenicity of SARS‐CoV‐2 Vaccines in Patients With Chronic Liver Diseases (CHESS‐NMCID 2101): A Multicenter Study. Clin Gastroenterol Hepatol. 2022;20(7):1516‐24.e2. - PMC - PubMed
    1. Kamar N, Abravanel F, Marion O, Couat C, Izopet J, Del Bello A. Three Doses of an mRNA Covid‐19 Vaccine in Solid‐Organ Transplant Recipients. N Engl J Med. 2021;385(7):661‐2. - PMC - PubMed

Publication types

Substances